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The human ATP-binding cassette family C member 6 (ABCC6 ) gene encodes an ABC
transporter protein expressed primarily in the liver and to a lesser extent in the kidneys and
the intestines.We review here the mechanisms of this restricted tissue-speciﬁc expression
and the role of hepatocyte nuclear factor 4αwhich is responsible for the expression pattern.
Detailed analyses uncovered further regulators of the expression of the gene pointing to
an intronic primate-speciﬁc regulator region, an activator of the expression of the gene by
binding CCAAT/enhancer-binding protein beta, which interacts with other proteins acting
in the proximal promoter. This regulatory network is affected by various environmental
stimuli including oxidative stress and the extracellular signal-regulated protein kinases
1 and 2 pathway. We also review here the structural and functional consequences of
disease-causing missense mutations of ABCC6. A signiﬁcant clustering of the missense
disease-causing mutations was found at the domain–domain interfaces. This clustering
means that the domain contacts are much less permissive to amino acid replacements
than the rest of the protein. We summarize the experimental methods resulting in
the identiﬁcation of mutants with preserved transport activity but failure in intracellular
targeting. These mutants are candidates for functional rescue by chemical chaperons.
The results of such research can provide the basis of future allele-speciﬁc therapy of
ABCC6-mediated disorders like pseudoxanthoma elasticum or the generalized arterial
calciﬁcation in infancy.
Keywords: ABCC6, HNF4α, 4-phenyl-butyrate, C/EBPβ, calcification, pseudoxanthoma elasticum, generalized
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THE ABCC6 PROTEIN
ATP-binding cassette family C member 6 (ABCC6) encodes an
ATP-dependent transporter primarily found in the plasma mem-
brane of hepatocytes (Madon et al., 2000). In vitro studies supports
that it functions as an organic anion efﬂux pump (Belinsky et al.,
2002; Iliás et al., 2002) transporting (an) unidentiﬁed substrate(s)
from the liver toward the circulation. The functional relationship
between ABCC6 and ectopic calciﬁcation is not understood.
On the basis of sequence similarity forty-eight ABC proteins
are annotated in the human genome and classiﬁed as mem-
bers of seven subfamilies. The ABC proteins share the general
structural features: they harbor two nucleotide-binding (ABC)
domains and two transmembrane domains (TMDs), each with
six membrane-spanning helices (the so called “core structure”).
The ABCC-subfamily consists of 12 proteins; most of them
are active transporters. Two additional domains are fused to
this core structure N-terminally in some ABCC-type proteins
(“long MRPs” like ABCC1, 2, 3, 6, 8, 9, and 10): a TMD with
ﬁve membrane embedded helices and an intracellular approx-
imately 80 amino acid long loop. The domain architecture
of this type of proteins, including ABCC6, can be described
like TMD0-L0-TMD1-ABC1-L1-TMD2-ABC2 [L0 and L1 are
intracellular loop (ICL); Figure 1B]. ABCC6 consists of 1503
amino acids and in vitro studies demonstrated the transport
of different organic anions, glutathione-conjugates like glu-
tathione S-conjugated leukotriene C4 (LTC4), N-ethylmaleimide
S-glutathione (NEM-GS), and S-(2,4-dinitrophenyl) glutathione
(Iliás et al., 2002), while the rat ortholog transports an anionic
cyclopentapeptide (Belinsky et al., 2002). It was found using an
in vitro transport assays that three of the missense mutations
described as causative variants in pseudoxanthoma elasticum
(PXE) result in the loss of ATP-dependent transport of test
substrates (Iliás et al., 2002). It has also been suggested that over-
expression of ABCC6 is able to confer low levels of resistance
to several commonly used natural product anticancer agents like
etoposide, doxorubicin, daunorubicin, and actinomycin D (Belin-
sky et al., 2002). However, clinically relevant ABCC6-mediated
drug resistance has never been found.
Since the ﬁrst PXE-causing mutations were discovered
(Bergen et al., 2000; Le Saux et al., 2000, 2001; Ringpfeil
et al., 2000), the number of identiﬁed disease-causing variants
has exceeded 350. By searching PubMed papers reporting
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FIGURE 1 | Membrane topology, homology model and in vivo
localization of humanABCC6 and its mutants (based on
Le Saux et al., 2011). (A) Homology model of human ABCC6. The
position of the missense mutants studied are indicated. (B) Membrane
homology model of human ABCC6. The domain structure are indicated on
the top, the position of missense mutants are shown in red. (C) Colocalization
of the endogenous mouse Abcc6 (red) and human ABCC6 (green) in vivo
in mouse liver after HTVI-delivery of ABCC6 cDNA by confocal microscopy.
Arrows indicate the basolateral localization on Z-stack cross/sections. (D)
Effect of 4-PBA on membrane targeting of Q1314W. Left panel :
colocalization of the endogenous mouse Abcc6 (red) and human
ABCC6 mutant (green) in vivo in mouse liver after HTVI-delivery of ABCC6
cDNA without 4-PBA treatment (upper panel ) or with 4-PBA treatment
(lower panel ). Right panel : colocalization of the endogenous dog
Na/K-ATPase (red) and human ABCC6 mutant Q1314W (green) in vitro in
polarized MDCKII cells without 4-PBA treatment (upper panel ) or with 4-PBA
treatment (lower panel ). White arrows point to the altered membrane
localization.
ABCC6 mutations and polymorphisms an internet-based muta-
tion/variation database of ABCC6 has been established. Upon
creating the database approximately 300 published mutations
in 51 publications by 23 corresponding authors were col-
lected and 65 potential errors in the reported mutations or
sequences were found. Only corrected (conﬁrmed) mutations
are included into the database (Váradi et al., 2011), which
contains now nearly 400 mutation/variations of the gene
(http://www.ncbi.nlm.nih.gov/lovd/home.php?select_db=ABCC6).
The majority of the mutations are missense. Despite the large
number of PXE-speciﬁc mutations that has been identiﬁed in
ABCC6, no clear genotype–phenotype correlation has emerged.
No high-resolution three-dimensional structure of ABCC-type
is available. However, a three-dimensional homology model of
ABCC6 is already built and published (Fülöp et al., 2009), made
possible by using the coordinates of high-resolution crystalline
structures of other ABC proteins (Dawson and Locher, 2006;
Aller et al., 2009). Newly recognized structural elements are the
long “rigid” extensions of the transmembrane helices, called ICLs
were also obvious in the homology models. Each half of the ABC
proteins has two ICLs interacting with theABCdomains. The cou-
pling helices contact with their“own”as well as with the“opposite”
ABCdomains, hence a special type of domain swapping can be rec-
ognized in the structure (see insert on Figure 1A). The homology
models constructed can be interactively studied using the ABCC6
database.
The disease-causing mutations in the protein are distributed
on an uneven fashion and performing statistical analysis signif-
icant clustering of the missense PXE mutations was found at
the domain–domain interfaces: at the transmission interface that
involves four ICLs and the two ABC domains as well as at the
ABC–ABC contact surfaces. In the nucleotide-saturated model
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the mutations affecting these regions are 2.75- and 3.53-fold
more frequent than the average mutational rate along the pro-
tein sequence, respectively (Fülöp et al., 2009). At the predicted
ICL–ABC interfaces in the nucleotide-free model the mutational
rate is 4.25-fold more frequent than the average mutational rate
along the protein sequence (the ABC domains are distant in this
conformation; Váradi et al., 2011). The observed signiﬁcant clus-
tering means that the domain contacts are much less permissive to
amino acid replacements than the rest of the protein. These results
provide a “bridge” between genetic data and protein structure and
can be viewed as novel proof of the importance of the studied
domain–domain interactions in the ABCC6 transporter.
A systematic experimental study has been initiated to inves-
tigate the impact of missense disease-causing mutation in order
to better understand the molecular failure triggered by different
mutations. Amino acid substitutions in large plasma membrane
proteins such as ABCC6 generally result in decreased activity,
major conformation changes, low level of plasma membrane
targeting or a combination thereof. Therefore, studying the
consequences of naturally occurring disease-causing missense
mutations can provide important insights into the relationship
between protein structure and function, which may later assist in
the development of therapeutic applications (Le Saux et al., 2011).
We review here the major steps of this systematic experimental
study.
The complex experimental repertoire consists of expression
and biochemical characterization of the protein variants, inves-
tigation of their plasma membrane vs. intracellular localization in
polarized cell cultures. Finally, investigation the in vivo stability
and cellular location of mutated ABCC6 in fully differentiated
hepatocytes by transiently expressing the human mutant pro-
teins was performed in the liver of C57BL/6J mice. Five missense
mutations, V1298F and G1321S in the C-proximal ABC domain
and R1138Q, R1314W, and R1339C at the transmission inter-
face were included into the study. The location of the mutated
residues is illustrated on Figure 1A. An N-terminal truncated
mutant, del1−277ABCC6 (DABCC6) missing the TMD0 and L0
domains has also been constructed as a control (see Figure 1B).
The results are summarized in Table 1. In detail: the wt ABCC6
is fully functional in the biochemical transport and enzymatic
(MgATP-binding and catalytic intermedier formation) assays, it
is integrated into the basolateral membrane of polarized Madin–
Darby canine kidney type II (MDCKII) cells in vitro as well as that
of the mouse hepatocytes in vivo. The DABCC6 appears to be an
ideal negative control as it is inactive, and localized intracellularly
both in MDCKII cells and in mouse liver cells.
The R1139C mutant did not result in native size protein when
expressed in Sf9 cells indicating folding problems. Two of the vari-
ants (V1298F and G1321S) were found to be inactive, though
they were capable of binding MgATP, their capacity to form a cat-
alytic intermediate (“occluded nucleotide state”) was impaired.
R1138Q and R1314W were fully active in the transport assay.
When overexpressed in MDCKII cells surprisingly, R1139C show
a level of protein expression similar to the wild type, however, it
was found intracellularly, indicating that the mutation triggered
an altered conformation not compatible with plasma membrane
targeting. The same was true for mutants G1321S, R1338Q, and
R1314W, while the inactive V1298F was found mostly in the
plasma membrane.
ATP-binding cassette transporters are traditionally studied in
cultures of kidney-derived MDCKII cells, but these are not ideal
for studying hepatic proteins, as they do not correspond to the
physiology of the liver where ABCC6 is primarily present. To over-
come these obstacles hydrodynamic tail vein injection (HTVI)
method was utilized to study the human ABCC6 protein in the
fully differentiated liver of a living mouse. This method delivered
DNA to the liver very effectively (Liu et al., 1999; Zhang et al., 2004)
and ensured the selective hepatic expression of the wt human pro-
tein in mouse liver with an adequate basolateral targeting (see
Figure 1C).
The in vivo intracellular localization of the human variants
was also studied. Only the inactive V1298F mutant showed
plasma membrane localization at a similar high level as the wt.
The R1339C and the G1321S proteins were found intracellularly
(similar to the results obtained in the in vitro cell culture system).
R1138Q and R1314W showed mostly intracellular appearance,
Table 1 | Function and intracellular localization of ABCC6 variants.
ABCC6
variant
Stability
in Sf9
MgATP-
binding
ATPase catalytic
intermediate
Transport activity
(% ofWT)
Plasma membrane
localization in
MDCKII cells
Plasma membrane
localization in
mouse liver
Intracellular localization
in mouse liver
WT Stable Yes Yes 100 +++++ +++++ −
DABCC6 Stable n.d. n.d. <10 − − +++++
R1138Q Stable Yes Yes ∼85 ++++ ++ +++
V1298F Stable Yes No <10 +++++ +++++ −
G1321S Stable Yes No <10 − − +++++
R1314W Stable Yes Yes ∼90 − + ++++ (ER)
R1339C Unstable n.a. n.a. n.a. − − +++++
n.d., not determined; n.a., not applicable; ER, mostly retained with the endoplasmic reticulum.
The symbol “+” represents semiquantitative estimate of the presence of immunohistochemical signal in the given compartment (+++++ is maximal abundance).
The symbol “−” represents absence of immunohistochemical signal in the given compartment.
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however, a portion of the protein could reach the plasma
membrane.
From the above the functional features and the pathogenic
character of the mutants can be delineated. They clarify the bio-
chemical and cellular effects of ABCC6 mutations that lead to
dystrophic calciﬁcation in humans. Most probably the dramati-
cally reduced transport activity of mutants V1298F and G1321S
is the molecular background of the disease in patients with these
variants (irrespective that in the case of the former one the correct
plasma membrane targeting is preserved). In the case of R1338,
R1314, and R1339 the aberrant folding resulted by the mutation
prevents plasma membrane localization, which seems to be the
prerequisite of the normal physiological function (irrespective that
two of these mutants are active as organic anion transporter).
The successful completion of these experiments may provide
valuable basic results and those in the ﬁeld of translationalmedical
research. They indicate the potential for therapeutic interventions
to correct the defects of a mutant ABCC6 protein. Mutants with
preserved transport activity but failure in intracellular targeting
are candidates for functional rescue.
Several studies have shown that sodium 4-phenylbutyrate (4-
PBA) can act as a chemical chaperone (e.g., Rubenstein andZeitlin,
2000; van der Velden et al., 2010) for misfolded proteins in the
endoplasmic reticulum (ER). Therefore, it was studied whether
pre-treating mice with 4-PBA before HTVI would restore normal
cellular trafﬁcking of those mutants that retained transport activ-
ity. R1138Q and R1314W were tested, along with R1339C and
the WT protein as non-functional and functional controls respec-
tively. It is expected that those mutant proteins retained in the ER
are to be rescued by 4-PBA. We have found that R1314 shows ER
retain, as it colocalized with an ER-marker in mouse hepatocytes,
while R1338Q and R1339C was not found in this location.
Oral treatment of the animalswith 4-PBAbeforeHTVI resulted
in no effect on the intracellular localization of R1338Q and
R1339C. However, treatment of mice with 4-PBA improved the
cellular localization of R1314W (Figure 1D, left panels), which
was conﬁrmed in MDCKII cells (Figure 1D, right panels). This
result suggests that the incorrect intracellular trafﬁcking of this
otherwise functional mutant is due to ER retention, implicating
protein misfolding, and that correct intracellular trafﬁcking of an
otherwise functional mutant can be restored. As 4-PBA is an FDA-
approved drug, these results may facilitate further clinical research
for allele-speciﬁc therapy of PXE.
TRANSCRIPTIONAL REGULATION OF THE ABCC6 GENE
However, we should also keep in mind that PXE is not a single
disease but a group of similar phenotypes, which is constituted
by PXE, PXE-like diseases and generalized arterial calciﬁcation of
infancy (GACI; Aessopos et al., 1992, 2008; Vanakker et al., 2007;
Nitschke et al., 2012) based on various,mostly unknownpathome-
chanisms. Therefore, another therapeutical approach for at least
some PXE(-like) diseases could be targeted to the gene instead of
the misfolded protein. In order to explore this idea we have to go
back to the transcriptional regulation of ABCC6.
Although some studies have reported ubiquitous expression of
ABCC6 (Beck et al., 2003, 2005), there is a consensus in the lit-
erature that the gene is primarily expressed in the liver and to
a much lower extent in the kidneys (Kool et al., 1999; Madon
et al., 2000; Beck et al., 2005; Maher et al., 2005, 2006). There is
also intestinal expression of the gene based on the data published
by (Kool et al., 1999) and ﬁndings in human cell lines (Ratajew-
ski et al., 2012). This expression pattern is similar in rodents and
humaneven if the gene is in adynamically evolving genomic region
(Eichler et al., 2007; Symmons et al., 2008). This fast evolution is
characterized by numerous recent segmental duplications but also
some primate-speciﬁc insertions/deletions with uncovered regu-
latory role, in spite of the relatively high conservation level of the
coding region and some other regulatory sequences (Eichler et al.,
2007; Symmons et al., 2008; Ratajewski et al., 2012). Why the gene
is expressed essentially in the liver and to a lower level in very
few other tissues, while in the organs suffering from the loss-of-
function ABCC6 mutations ABCC6 is normally not expressed? To
formulate this question in a different way: what is responsible for
this intriguing tissue-speciﬁcity?
To answer this question a battery of molecular biological tools
and assays were used, e.g., luciferase reporter gene assay, gel shift
assay (EMSA), transcription factor microarray, DNase I hyper-
sensitivity assay (DHA), and chromatin immunoprecipitation
(ChIP). Bioinformatic studies revealed the existence of two evolu-
tionarily well-conserved sequence blocks: one in a distal 5′ region,
near to the neighboring NOMO3 gene, and one in the proximal
promoter of the ABCC6 gene (Arányi et al., 2005). Similar data
were reported in human cell lines (Arányi et al., 2005) and mouse
tissues (Douet et al., 2007) showing that in the proximal pro-
moter, the presence of silencing epigenetic factors, namely DNA
methylation, correlates inversely with the expression level of the
gene, suggesting that the regulation of tissue-speciﬁc expression is
determined by this region.
An important number of luciferase reporter gene assays were
performed to ﬁnd the regulatory elements in the promoter and
later for the identiﬁcation of transcription factors binding those
elements (Arányi et al., 2005; Douet et al., 2006, 2007; Jiang
et al., 2006; Ratajewski et al., 2006, 2008, 2009, 2012; de Bous-
sac et al., 2010; Martin et al., 2011). In these experiments the
ﬁreﬂy luciferase gene is under the transcriptional control of a
target sequence in a plasmid vector. After transient transfec-
tion of the plasmid the transcriptional regulatory capacity of the
target sequence is estimated by the luminometric luciferase enzy-
matic activity measurement. The use of this technique revealed a
DNAmethylation-dependent activatory (−332/+72 relative to the
translation start site) and a repressor region (−718/−332; Arányi
et al., 2005; Jiang et al., 2006). The −332/+72 fragment turned
out to be composed of a −145/+72 core promoter (characterized
by a ubiquitous low activity in the assay in all cell types tested
and not sensitive to DNA methylation (Arányi et al., 2005; Rata-
jewski et al., 2006, 2012; de Boussac et al., 2010) and two other
fragments located between −209/−145 and −233/−209 both
sequences active in a cell type-speciﬁc manner (Ratajewski et al.,
2009, 2012; de Boussac et al., 2010). Furthermore, it has also been
shown that the activity of theprimate-speciﬁc−233/−209 element
depends on the activity of the −209/−145 sequence (Ratajewski
et al., 2009, 2012).
Another set of luciferase reporter gene assays were carried out
based on the results obtained by DHA. This classical method
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reveals accessible regions to partial DNase I digestion in intact
nuclei (Lu and Richardson, 2004). The accessible regions fre-
quently represent active transcriptional regulatory elements. Sur-
prisingly, the data suggested that not only the proximal promoter
but also the ﬁrst intron of the human ABCC6 gene might have
an important tissue- or cell type-speciﬁc regulatory role in the
control of the expression of the gene (Ratajewski et al., 2012).
Later on, with the help of the luciferase assays the presence of
an important primate-speciﬁc sequence in the ﬁrst intron of the
gene (+629/+688) was found, which multiplies by several fold the
transcriptional activity of the proximal promoter alone (Ratajew-
ski et al., 2012). This intronic sequence and the proteins binding
to turned out to depend on the presence of the proximal pro-
moter and more speciﬁcally on the −233/−209 element, with
which it might interact directly. Interestingly both sequences are
primate-speciﬁc. These two elements also interact with the pro-
tein binding the sequence −209/−145, which is an evolutionarily
highly conserved fragment (Ratajewski et al., 2012).
In another series of experiments, the different proteins rec-
ognizing the response elements were identiﬁed. Either luciferase
assays with mutated target regulatory sequences or luciferase plas-
mids co-expressed with candidate transcription factors were used
(Douet et al., 2006; Jiang et al., 2006; Ratajewski et al., 2006, 2008,
2009, 2012; de Boussac et al., 2010). Another approach was the
EMSA, when the in vitro binding of a protein from a nuclear
extract or its recombinant form is tested. In these cases in general
short, labeled oligonucleotides are used as probe and in case of
binding a protein, upon acrylamide gel electrophoresis a delay in
the migration can be observed relative to that of the free probe
(Douet et al., 2006, 2007; Jiang et al., 2006; Ratajewski et al., 2008,
2009). The transcription factor array is based on a similar principle
[the hybridization of DNAand speciﬁc transcription factors (Jiang
et al., 2006; Martin et al., 2011). Finally, ChIP can immunoprecip-
itate a target protein reversibly linked to its target sequence in the
natural chromatin context after fragmentation of the chromatin.
The immunoprecipitated fraction can then be tested by qPCR to
determine the binding of the target protein to the sequences of
interest (Douet et al., 2006, 2007; Ratajewski et al., 2006, 2008,
2012; de Boussac et al., 2010; Martin et al., 2011)]. These tech-
niques led different groups to demonstrate the crucial regulatory
role of hepatocyte nuclear factor 4 (HNF4) both in the human
(de Boussac et al., 2010) and mouse (Douet et al., 2006) ABCC6
gene. HNF4 binds to an evolutionarily highly conserved degener-
ate site between −209/−145 (de Boussac et al., 2010; Ratajewski
et al., 2012). These data demonstrate the role of this transcrip-
tion factor, which is a master regulator of metabolic genes in
the liver. Interestingly, ABCC6 is expressed only in tissues where
HNF4 is also present, suggesting that this transcription factor
determines the tissue-speciﬁc expression of ABCC6. Our data also
showed that in spite of the very important role of HNF4, it does
not confer very high transcriptional activity to the gene. Further
experiments suggested the binding of several other transcription
factors to the proximal promoter [PLAG family members (Rata-
jewski et al., 2008, 2009), RXR (Ratajewski et al., 2006), SP1 and
TGF-β (Jiang et al., 2006), and SP1 and NF-E2 in mouse (Douet
et al., 2006, 2007; Martin et al., 2011)], however, the potential role
of these different proteins is still unclear. The important role of
CCAAT/enhancer-binding protein beta (C/EBPβ) in activating the
transcription of the gene by binding the primate-speciﬁc sequence
in theﬁrst intronwas also shown (Ratajewski et al., 2012). Ourdata
also suggest the binding of C/EBPα (unpublished).
In the previous sections we have summarized the regulatory
elements in the ABCC6 gene and the transcription factors binding
them. Altogether this network governs the tissue-speciﬁc tran-
scriptional regulation of the expression of the gene. However, there
is a third layer of investigations, which focused on the regulation
of the ABCC6 gene expression by environmental factors. These
experiments showed that the extracellular signal-regulated pro-
tein kinases 1 and 2 (ERK1/2) cascade negatively regulates the
expression of the gene (de Boussac et al., 2010). It was shown that
this inhibition converges on HNF4, which due to the activation
of ERK1/2 looses its activator potential in two phases. Similarly, it
was shown that oxidative stress inhibits the expression of the gene
in human cell lines. This effect is probably also at least partially
acting via the ERK pathway (de Boussac et al., 2010). The role of
oxidative stress in the downregulation of the mouse Abcc6 gene
expression was shown in a beta-thalassemia model mouse. In this
model the role of NF-E2 transcription factor was described (Mar-
tin et al., 2011). Finally, the oxidative stress factors or other agents
present in the serum of PXE patients were shown to downregu-
late the expression of the human gene in cell culture systems. The
detailed molecular mechanism behind this observation remains
to be deciphered (Le Saux et al., 2006). Altogether these ﬁndings
described in these sections above are summarized on (Figure 2).
What are the future questions in the ﬁeld? Can we use the
obtained information either in the better understanding or in the
cure of the disease? The major, still remaining question in the PXE
ﬁeld is the identiﬁcation of the molecule the ABCC6 protein is
transporting. Although, the better understanding of the transcrip-
tional regulation of the gene will not directly provide an answer
to this question however, it might give some hints. For example,
since the gene is downregulated by reactive oxygen species (ROS)
it probably does not play a role in the transport of molecules par-
ticipating in the ROS pathways. Similarly, as HNF4 and C/EBP
transcription factors regulate the expression of metabolic genes,
this might suggest that ABCC6 transports a common metabolite.
FIGURE 2 | Schematic model of the transcriptional regulation of the
humanABCC6 gene. Growth factors inhibit the expression of ABCC6 via
the activation of ERK1/2 cascade, which reduces HNF4α binding to the
promoter. In the intron, a transcriptional activator sequence binds C/EBPβ
and another hypothetical protein (Factor X). These proteins interact with a
complex formed by HNF4α and another factor (Y) binding the promoter,
activating the transcription of the gene.
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Concerning the use of the knowledge obtained from these studies
in the clinics, the situation is encouraging as in various clinical con-
ditions [carriers of PXE mutations (Köblös et al., 2010; Vanakker
et al., 2011) and secondary PXE (Aessopos et al., 1992, 2008)] the
increase of the expression of the ABCC6 gene could lead to an
improvement of the symptoms. Therefore, we consider that con-
tinuing the research to ﬁnd the molecular mechanisms governing
the regulation of the ABCC6 expression will lead to both a bet-
ter understanding of the pathomechanism of the disease and an
improvement of PXE related clinical phenotypes.
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